[go: up one dir, main page]

NO20062950L - 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet - Google Patents

5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet

Info

Publication number
NO20062950L
NO20062950L NO20062950A NO20062950A NO20062950L NO 20062950 L NO20062950 L NO 20062950L NO 20062950 A NO20062950 A NO 20062950A NO 20062950 A NO20062950 A NO 20062950A NO 20062950 L NO20062950 L NO 20062950L
Authority
NO
Norway
Prior art keywords
dlpyrimidines
diaminopyrazolo
pde
inhibitory activity
inhibitory
Prior art date
Application number
NO20062950A
Other languages
English (en)
Other versions
NO336526B1 (no
Inventor
Kevin Neil Dack
David Nathan Abraham Fox
Andrew Ian Morrell
Michael John Palmer
Andrew Simon Bell
David Graham Brown
Ian Roger Marsh
Carol Ann Winslow
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20062950L publication Critical patent/NO20062950L/no
Publication of NO336526B1 publication Critical patent/NO336526B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med formel (I)
NO20062950A 2003-11-24 2006-06-23 5,7-diaminopyrazol [4,3-d]pyrimidiner med PDE-5 inhiberende aktivitet og farmasøytisk sammensetninger NO336526B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0327319.0A GB0327319D0 (en) 2003-11-24 2003-11-24 Novel pharmaceuticals
PCT/IB2004/003747 WO2005049616A1 (en) 2003-11-24 2004-11-12 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY

Publications (2)

Publication Number Publication Date
NO20062950L true NO20062950L (no) 2006-08-23
NO336526B1 NO336526B1 (no) 2015-09-21

Family

ID=29764364

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062950A NO336526B1 (no) 2003-11-24 2006-06-23 5,7-diaminopyrazol [4,3-d]pyrimidiner med PDE-5 inhiberende aktivitet og farmasøytisk sammensetninger

Country Status (43)

Country Link
EP (1) EP1689751B1 (no)
JP (1) JP4056015B2 (no)
KR (2) KR100848216B1 (no)
CN (4) CN101362764B (no)
AP (1) AP2227A (no)
AR (1) AR046711A1 (no)
AT (1) ATE485297T1 (no)
AU (1) AU2004290643B2 (no)
BR (1) BRPI0416869A (no)
CA (1) CA2546987C (no)
CR (1) CR8416A (no)
CY (1) CY1110933T1 (no)
DE (1) DE602004029705D1 (no)
DK (1) DK1689751T3 (no)
EA (1) EA011772B1 (no)
EC (1) ECSP066580A (no)
ES (1) ES2351622T3 (no)
GB (1) GB0327319D0 (no)
GE (1) GEP20084528B (no)
HR (1) HRP20100651T1 (no)
IL (1) IL175433A (no)
IS (1) IS8406A (no)
MA (1) MA28172A1 (no)
ME (1) ME01216B (no)
MX (1) MXPA06005914A (no)
MY (1) MY140872A (no)
NL (1) NL1027568C2 (no)
NO (1) NO336526B1 (no)
NZ (1) NZ548097A (no)
OA (1) OA13289A (no)
PA (1) PA8617701A1 (no)
PE (1) PE20051061A1 (no)
PL (1) PL1689751T3 (no)
PT (1) PT1689751E (no)
RS (1) RS51556B (no)
SG (1) SG133614A1 (no)
SI (1) SI1689751T1 (no)
TN (1) TNSN06154A1 (no)
TW (1) TWI265031B (no)
UA (1) UA81994C2 (no)
UY (1) UY28625A1 (no)
WO (1) WO2005049616A1 (no)
ZA (1) ZA200602899B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリダジン誘導体
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1830837B1 (en) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
AR051090A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR051093A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
JP2008517994A (ja) * 2004-10-28 2008-05-29 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 新規医薬品
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
NL1029244C2 (nl) * 2005-06-10 2006-12-12 Ronald Silfried Marlin Middel ter vergroting van het mannelijk geslachtsorgaan.
DE102005050377A1 (de) * 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
NL2000291C2 (nl) * 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
WO2008132589A1 (en) * 2007-05-01 2008-11-06 Pfizer Limited Combinations comprising pregabalin
WO2009050554A2 (en) * 2007-10-19 2009-04-23 Pfizer Inc. Treatment of central nervous system disorders
DE102008063992A1 (de) * 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
EP2751116B1 (en) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク APP、BACE1、およびBACE2の阻害剤としての複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
JP6162820B2 (ja) 2012-12-19 2017-07-12 ファイザー・インク 炭素環式および複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
JP2016507551A (ja) 2013-02-13 2016-03-10 ファイザー・インク ヘテロアリール置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EA201591360A1 (ru) 2013-02-19 2016-03-31 Пфайзер Инк. Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
CA2925743C (en) 2013-10-04 2018-03-06 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
CA2934391A1 (en) * 2013-12-20 2015-06-25 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
DK3126361T3 (da) 2014-04-01 2020-01-02 Pfizer Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer
AP2016009521A0 (en) * 2014-04-04 2016-10-31 Lundbeck & Co As H Halogenated quinazolin-thf-amines as pde1 inhibitors
SG11201607896YA (en) 2014-04-10 2016-10-28 Pfizer 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
PT3177624T (pt) 2014-08-06 2019-07-11 Pfizer Compostos de imidazopiridazina
MX368162B (es) * 2014-12-08 2019-09-20 Janssen Sciences Ireland Uc Derivados de pirazolo[1,5-a]pirimidina sustituida con piperidina con actividad inhibidora sobre la replicacion del virus sincicial respiratorio (vsr).
EA033423B1 (ru) 2015-02-03 2019-10-31 Pfizer Циклопропанбензофуранилпиридопиразиндионы
MX389753B (es) 2015-06-17 2025-03-20 Pfizer Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
BR112018003489A2 (pt) 2015-09-24 2018-09-25 Pfizer n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
CA3015166C (en) 2016-02-23 2021-08-03 Pfizer Inc. 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
EP3478679B1 (en) 2016-07-01 2021-04-21 Pfizer Inc. 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
ES2937236T3 (es) 2017-06-22 2023-03-27 Pfizer Derivados de dihidro-pirrolo-piridina
AR115015A1 (es) 2018-03-23 2020-11-18 Pfizer Derivados de azaespiro piperazina
MX2020013083A (es) 2018-06-04 2021-05-27 Exscientia Ltd Compuestos de pirazolopirimidina como antagonistas del receptor de adenosina.
EP3840755A4 (en) * 2018-08-24 2022-04-20 Terns, Inc. THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN114375193B (zh) 2019-09-12 2024-05-14 拓臻制药公司 甲状腺激素受体β激动剂化合物
EP4097106A1 (en) * 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
US12144815B2 (en) 2021-02-23 2024-11-19 Hoth Therapeutics, Inc. Use of aprepitant for treating Alzheimer's disease
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
TW202506131A (zh) 2023-04-07 2025-02-16 美商拓臻製藥公司 GLP-1R及THRβ激動劑之組合以及其使用方法
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
DK1123296T3 (da) * 1998-10-23 2003-12-08 Pfizer Pyrazolopyrimidinon cGMP PDE5-inhibitorer til behandling af seksuel forstyrrelse
GB9823102D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
DE10031236A1 (de) * 2000-06-27 2002-01-10 Qiagen Gmbh Verwendung von Carbonsäuren und anderen Additiven in Kombination mit kationischen Verbindungen zur Stabilisierung von Nukleinsäuren in biologischen Materialien
DE10031584A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
DK1620437T3 (da) * 2003-04-29 2009-08-24 Pfizer Ltd 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension

Also Published As

Publication number Publication date
EP1689751A1 (en) 2006-08-16
EA200600677A1 (ru) 2006-12-29
AR046711A1 (es) 2005-12-21
PT1689751E (pt) 2010-11-29
SI1689751T1 (sl) 2011-01-31
ME01216B (me) 2013-03-20
ES2351622T3 (es) 2011-02-08
IS8406A (is) 2006-04-10
ECSP066580A (es) 2006-12-20
CR8416A (es) 2006-11-15
EA011772B1 (ru) 2009-06-30
JP4056015B2 (ja) 2008-03-05
PE20051061A1 (es) 2005-12-12
BRPI0416869A (pt) 2007-03-27
CA2546987C (en) 2009-05-12
CN101362764A (zh) 2009-02-11
UA81994C2 (en) 2008-02-25
CN101647802A (zh) 2010-02-17
AU2004290643A1 (en) 2005-06-02
NL1027568A1 (nl) 2005-05-26
IL175433A0 (en) 2006-09-05
HK1099286A1 (en) 2007-08-10
TW200520758A (en) 2005-07-01
PA8617701A1 (es) 2005-08-04
NZ548097A (en) 2008-12-24
IL175433A (en) 2011-08-31
AP2227A (en) 2011-03-29
JP2007512314A (ja) 2007-05-17
DE602004029705D1 (de) 2010-12-02
TWI265031B (en) 2006-11-01
KR20070026334A (ko) 2007-03-08
HK1128917A1 (en) 2009-11-13
NL1027568C2 (nl) 2005-11-30
OA13289A (en) 2007-01-31
KR100848216B1 (ko) 2008-07-24
ZA200602899B (en) 2007-07-25
CA2546987A1 (en) 2005-06-02
HRP20100651T1 (hr) 2011-01-31
AU2004290643B2 (en) 2008-08-07
CN1882591B (zh) 2011-08-10
WO2005049616A8 (en) 2006-06-01
DK1689751T3 (da) 2011-01-17
ATE485297T1 (de) 2010-11-15
MY140872A (en) 2010-01-29
GB0327319D0 (en) 2003-12-24
KR100893999B1 (ko) 2009-04-20
TNSN06154A1 (fr) 2007-11-15
UY28625A1 (es) 2005-06-30
EP1689751B1 (en) 2010-10-20
WO2005049616A1 (en) 2005-06-02
CN101362765B (zh) 2011-02-02
RS51556B (sr) 2011-06-30
MA28172A1 (fr) 2006-09-01
SG133614A1 (en) 2007-07-30
AP2006003591A0 (en) 2006-04-30
NO336526B1 (no) 2015-09-21
KR20080052666A (ko) 2008-06-11
GEP20084528B (en) 2008-11-10
CN1882591A (zh) 2006-12-20
CY1110933T1 (el) 2015-06-10
MXPA06005914A (es) 2006-06-27
CN101362764B (zh) 2011-04-20
PL1689751T3 (pl) 2011-03-31
CN101362765A (zh) 2009-02-11

Similar Documents

Publication Publication Date Title
NO20062950L (no) 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
NO20054404L (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
WO2004035569A3 (de) Neue verbindungen mit antibakterieller aktivität
NO20050199L (no) Azadisyklo-oktan og nonanderivater med DDP-IV-inhiberende aktivitet
DE60330150D1 (en) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
ATE369370T1 (de) Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
ATE360627T1 (de) Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
GEP20074198B (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials
NO20060230L (no) Nye aminobenzofenonforbindelser
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
NO20064415L (no) Nye amido-substituerte hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer
GB0229081D0 (en) Multifunctional cationic photoinitiators, their preparation and use
BRPI0416678A (pt) pirazolpirimidinas
CO5680420A2 (es) Compuestos de 6-amino-1h-indazol y 4-aminobenzenofurano como inhibidores de la fosfodiesterasa 4
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
DK1742950T3 (da) Pyrazolo-[4,3-D]-pyrimidiner
GB0215392D0 (en) Chemical compounds
EA200601106A1 (ru) Трициклические имидазопиридины для применения в качестве ингибиторов желудочной секреции
DE602004031878D1 (de) Immunhemmende pyrazolon-verbindungen
ATE276259T1 (de) Dihydroporphyrinderivate und ihre verwendung

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees